Risk of cardiovascular disease and death in patients with breast cancer receiving anthracycline-based therapy: A retrospective cohort study
To prevent cardiovascular event onset in patients with breast cancer undergoing anthracycline-based chemotherapy, thorough monitoring is essential, especially in patients of advanced age, those with comorbid hypertension, and those undergoing trastuzumab treatment.
Authors
- Yoon Jae Lee (ORCID: https://orcid.org/0000-0002-1532-0942)
- Yu‐Cheol Lim (ORCID: https://orcid.org/0000-0001-8601-3117)
- In‐Hyuk Ha (ORCID: https://orcid.org/0000-0002-5020-6723)
- Ye‐Seul Lee (ORCID: https://orcid.org/0000-0001-6127-5401)
Institutions
- Jaseng Medical Foundation (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1371/journal.pone.0335083
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00